mtor-independent

TFEB activator 1 (Curcumin analog compound C1) is an activator of transcription factor EB (TFEB) with promise for the prevention or treatment of Alzheimer's disease.

RU-SKI 43 is a potent and selective hedgehog acyltransferase (Hhat) inhibitor with an IC50 of 850 nM. It exhibits anticancer activity and is a potential treatment for lung adenocarcinomas. RU-SKI 43 reduces Gli-1 activation through smoothening-independent non-canonical signaling and inhibits Akt and mTOR pathway activity.

BRD5631 is an autophagy enhancer that operates through an mTOR-independent pathway. It influences several cellular disease phenotypes associated with autophagy, such as protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production. BRD5631 can serve as a valuable tool for studying the role of autophagy in cellular homeostasis and disease. [1].

SMER18 is a small molecule enhancer of rapamycin, functioning as an mTOR-independent autophagy inducer.

SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells via an mTOR-independent mechanism and prevented the accumulation of amyloid beta peptide.

8-Aminoadenosine (8-NH2-Ado) is an RNA-directed nucleoside analogue that effectively diminishes cellular ATP levels and impedes mRNA synthesis. It also obstructs Akt/mTOR signaling, inducing autophagy and apoptosis in a p53-independent manner. Its significant antitumor activity underscores its therapeutic potential.

Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, exhibits potent antiproliferative activity, induces autophagosome accumulation via an mTOR-independent mechanism, and triggers apoptosis. Furthermore, it inhibits VEGFA/VEGFR2 expression, effectively suppressing tumor growth in glioblastoma xenografts [1] [2].

EGFR-IN-79 (compound 21), an EGFR inhibitor, exhibits antitumor activity through ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. It effectively induces cell death in proliferating and quiescent zones of EJ28 spheroids and demonstrates a safety profile in zebrafish-based models [1].

Cucurbitacin D, a triterpenoid isolated from Ecballium elaterium (L.), exhibits anticancer and antitumor activity, inhibits glucose uptake and lactate production in metastatic PrC, and induces inflammasome activation independent of ERK1/2 activation. Cucurbitacin D, a novel inflammasome activator in macrophages, inhibits HepG2 cell proliferation and induces apoptosis by modulating the JAK/STAT3, PI3K/Akt/mTOR and MAPK signaling pathways, and can be used in the study of cervical cancer, leukemia, and prostate cancer.